Immatics N.V. (IMTX) vs Janux Therapeutics, Inc. (JANX)
A side-by-side comparison of Immatics N.V. and Janux Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMTX
Immatics N.V.
$7.51HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
JANX
Janux Therapeutics, Inc.
$16.72HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — IMTX vs JANX
growth of $100 · dividends reinvested · last 5yIMTX -36.9% (-8.8%/yr)JANX -34.2% (-8.0%/yr)JANX compounded faster over this window
IMTX JANX
IMTX vs JANX: by the numbers
- •JANX is the larger company ($1.02B vs $1.01B market cap).
- •Both run net losses; JANX's is the smaller (-321.81% vs -493.26% net margin).
- •JANX grew revenue faster over the past five years (105.89% vs 6.40% CAGR).
Metrics side by side
Valuation
| Metric | IMTX | JANX |
|---|---|---|
| P/S ratio | 20.75 | 31.97 |
| P/B ratio | 2.21 | 1.10 |
Profitability
| Metric | IMTX | JANX |
|---|---|---|
| Gross margin | 100.00% | 79.71% |
| Operating margin | -377.11% | -1576.67% |
| Net margin | -493.26% | -321.81% |
| ROE | -52.47% | -11.06% |
| ROIC | -53.36% | -15.15% |
Growth (annualized)
| Metric | IMTX | JANX |
|---|---|---|
| Revenue CAGR (5Y) | 6.40% | 105.89% |
| Total return CAGR (5Y) | -9.88% | -6.45% |
Frequently asked
- Which has grown faster, IMTX or JANX?
- Over the past five years, JANX grew revenue faster — IMTX at a 6.40% CAGR versus JANX at 105.89%.
- How have IMTX and JANX total returns compared?
- Over the past 5 years, IMTX delivered -9.88% and JANX delivered -6.45% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Immatics ROEJanux Therapeutics ROEImmatics operating marginJanux Therapeutics operating marginImmatics revenue growthJanux Therapeutics revenue growthImmatics free cash flowJanux Therapeutics free cash flow
Immatics & Janux Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.